Irish headquartered US pharma group Mallinckrodt has been accused of “buying the support” of a select group of creditors with an $80 million cash fee payment on the eve of bankruptcy, filings to the US District Court of Delaware show. The objection by second lien creditor United Equities was one of several to be lodged last week against the group’s proposed restructuring plan. It is the group’s second insolvency outing in the last 18 months.  United Equities says it holds approximately $17.5 million in Second Lien Notes – creditors in this class are slated to receive an 11-16 per cent recovery…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €50.

Subscribe

Cancel at any time.

Are you already a member? .